The aims of the 340B program are important. But, unfortunately, there is little evidence that the program is delivering on ...

Eli Lilly said on Thursday it sued the federal Health Resources and Services Administration (HRSA) over allegedly blocking ...

Eli Lilly is taking the HRSA to court after the latter allegedly blocked the pharma's plan on the manner of offering ...

The New Jersey-based drugmaker is trying to get the courts’ backing to pay hospitals rebates for two drugs in the 340B drug ...

Eli Lilly proposed a plan to ensure 340B entities pay no more than the ceiling price by providing them with cash directly on ...

Johnson & Johnson seeks to charge 340B-enrolled disproportionate share hospitals full price for Xarelto and Stelara and issue ...

Johnson & Johnson is escalating its fight with the federal government over its controversial plan to change how it doles out ...

The lawsuit is the second by a large drugmaker in recent days challenging how it provides required discounts to certain ...

Lindsay Bealor Greenleaf, JD, MBA, of ADVI Health, weighs in on what to expect in key health care policy areas in the wake of ...

Drugmaker Johnson and Johnson is suing the Department of Health and Human Services and the Health Resources and Services Administration for blocking its new 340B rebate model, and is seeking to verify ...

Discover how the 340B drug pricing program, intended to help low-income patients, has become a system of abuse and misuse ...

California is poised to pass a ballot measure aimed at imposing 340B spending restrictions for certain healthcare entities participating in the ...